타액 채취 및 진단 시장 규모, 점유율, 동향 분석 리포트 : 채취 부위별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Saliva Collection And Diagnostics Market Growth & Trends:

The global saliva collection and diagnostics market size is estimated to reach USD 1,100.2 million by 2030, registering a CAGR of 4.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Owing to the increasing prevalence of communicable and non-communicable diseases along with the increasing preference for non-invasive methods for disease diagnosis. Moreover, the growing need to diagnose COVID-19-infected symptomatic and asymptomatic patients have created significant opportunities for the market. In August 2022, a research study published in PLOS ONE stated that oral fluid samples could be used for various diagnostic assays, such as COVID-19, due to its storage and ease of sample collection. Moreover, researchers have also stated that even if the salivary samples were stored for more than 28 days, it would remain reliable and useful.

Furthermore, the global burden of cancer and related deaths rose in 2020, majorly because of the increasing aging population and socioeconomic development. In April 2020, an article published in the American Society of clinical oncology stated that more than 50% of cancers globally are diagnosed in people aged 65 and older. Therefore, the saliva-based test is considered to be the best non-invasive procedure to detect cancer. In August 2022, OrisDX announced of developing a saliva-based non-invasive molecular test to diagnose and detect oral cancer at an early stage which would help in improving patient outcomes.

There has been significant growth in the adoption of saliva samples for both clinical and research applications as it offers non-invasive sampling, easy, simple collection, and higher patient compliance, among others. Several advancements and developments are happening in saliva specimens which would advance the proteomics field. For instance, in September 2022, an article published in India Today stated that researchers from IIT Roorkee identified salivary proteins which could help in predicting metastatic triple-negative breast cancer.

Key players operating in the market are taking several initiatives such as entering into strategic alliances and launching new products which are contributing to the overall growth. For instance, in January 2021, OraSure Technologies, Inc. announced that its saliva collection device, OMNIgene*ORAL, has been selected by Chronomics Limited for the SARS CoV-2 PCR test. Similarly, in August 2020, Fluidigm Corporation announced receiving FDA authorization for its saliva-based test, Advanta Dx SARS-CoV-2 RT-PCR assay. This test would help to detect the presence of coronavirus in the sample.

Saliva Collection And Diagnostics Market Report Highlights:

• The growth of the overall saliva collection and diagnostics market is attributed to the increasing prevalence of infectious diseases along with the growing demand for non-invasive methods for disease detection
• By site of collection, the submandibular/sublingual gland collection segment dominated the market in 2024, owing to the increasing cases of sialoliths among the young population
• By application, the disease diagnostics segment dominated the market in 2024 owing to the increasing aging population globally coupled with increasing cases of diseases such as cancer, cardiovascular diseases, and others
• By end use, the diagnostic laboratories segment captured the highest market share in 2024, owing to the growing number of diagnostic labs along with the introduction of advanced technology which could help in the early detection of diseases
• By region, North America dominated the market in 2024 owing to the presence of several market players along with increasing support from the government to boost the demand in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Site of Collection
  • 1.2.2. Application
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Site of collection outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
• 2.3. Competitive Insights

Chapter 3. Saliva Collection and Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing cases of infectious disease
    • 3.2.1.2. Rising application of non-invasive saliva testing method
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of skilled professionals to operate saliva collection devices
• 3.3. Saliva Collection and Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Saliva Collection and Diagnostics Market: Site of Collection Estimates & Trend Analysis

• 4.1. Site of Collection Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Saliva Collection and Diagnostics Market by Site of Collection Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Parotid Gland Collection
    • 4.4.1.1. Parotid gland collection market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Submandibular/Sublingual Gland
    • 4.4.2.1. Submandibular/Sublingual Gland market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Others
    • 4.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Saliva Collection and Diagnostics Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Saliva Collection and Diagnostics Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Disease diagnostics
    • 5.4.1.1. Disease diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Forensic applications
    • 5.4.2.1. Forensic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Research
    • 5.4.3.1. Research market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Saliva Collection and Diagnostics Market: End-Use Estimates & Trend Analysis

• 6.1. End-Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Saliva Collection and Diagnostics Market by End-Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Dentistry
    • 6.4.1.1. Dentistry market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Diagnostic Laboratories
    • 6.4.2.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Pharmaceutical & Biotechnology Companies
    • 6.4.3.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Saliva Collection and Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Thermo Fisher Scientific Inc
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Neogen Corporation
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Abbott
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Sarstedt AG & Co.KG
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Autogen, Inc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Oasis Diagnostics
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Porex
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Salimetrics, LLC
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Takara Bio, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives